Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) — Cash Flow-to-Debt Ratio
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a Cash Flow-to-Debt Ratio of -0.02x as of June 2023, meaning its operating cash flow of €-64.53 Million could theoretically repay 0% of its total liabilities (€3.97 Billion) in one year. See Tianjin Zhong Xin Pharmaceutical Group C free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited across 13 annual periods. Also explore Tianjin Zhong Xin Pharmaceutical Group C net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
Year-by-year debt coverage analysis for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited. For market capitalisation and broader financial context, see how much is Tianjin Zhong Xin Pharmaceutical Group C worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | €461.07 Million | €4.59 Billion | ▼ -68.3% |
| 2024 | 0.32x | €924.67 Million | €2.92 Billion | ▲ +65.0% |
| 2023 | 0.19x | €688.49 Million | €3.58 Billion | ▲ +2.2% |
| 2022 | 0.19x | €677.25 Million | €3.61 Billion | ▼ -43.7% |
| 2021 | 0.33x | €852.40 Million | €2.55 Billion | ▲ +16.0% |
| 2020 | 0.29x | €671.42 Million | €2.33 Billion | ▲ +34.7% |
| 2019 | 0.21x | €495.49 Million | €2.32 Billion | ▲ +25.1% |
| 2018 | 0.17x | €350.14 Million | €2.05 Billion | ▲ +8679.3% |
| 2017 | 0.00x | €-3.97 Million | €2.00 Billion | ▼ -101.0% |
| 2016 | 0.20x | €417.77 Million | €2.06 Billion | ▲ +10.5% |
| 2015 | 0.18x | €360.58 Million | €1.96 Billion | ▲ +59.4% |
| 2014 | 0.12x | €286.85 Million | €2.49 Billion | ▲ +45.0% |
| 2013 | 0.08x | €213.44 Million | €2.69 Billion | — |